These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 26532)
1. Levodopa pharmacokinetics. Alterations after benserazide, a decarboxylase inhibitor. Doller HJ; Connor JD; Lock DR; Sloviter RS; Dvorchik BH; Vesell ES Drug Metab Dispos; 1978; 6(2):164-8. PubMed ID: 26532 [TBL] [Abstract][Full Text] [Related]
2. [Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, benserazide-HCl, on Parkinson's disease--Part II: Pharmacokinetic study (author's transl)]. Yokochi M; Kondo T; Hirayama K; Narabayashi H; Kuruma I No To Shinkei; 1979 Apr; 31(4):339-48. PubMed ID: 454549 [No Abstract] [Full Text] [Related]
3. Effect of L-dopa alone and with benserazide on the spontaneous activity of striatal neurones in normal and 6-hydroxydopamine-lesioned rats. Chang WY; Webster RA Br J Pharmacol; 1997 May; 121(2):331-7. PubMed ID: 9154345 [TBL] [Abstract][Full Text] [Related]
4. [Action of a peripheral inhibitor of dopa-decarboxylase on the inhibition by L-DOPA of the hypothalamo-hypophyseo-adrenocortical system in man]. Balestreri R; Bertolini S; Elicio N; Costa S Boll Soc Ital Biol Sper; 1974 Jul; 50(12):832-7. PubMed ID: 4447697 [No Abstract] [Full Text] [Related]
5. Pharmacokinetics of YM175, a new bisphosphonate, in rats and dogs. Usui T; Watanabe T; Higuchi S Drug Metab Dispos; 1995 Nov; 23(11):1214-9. PubMed ID: 8591721 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and metabolic studies of the decarboxylase inhibitor benserazide in animals and man. Schwartz DE; Brandt R Arzneimittelforschung; 1978; 28(2):302-7. PubMed ID: 580398 [No Abstract] [Full Text] [Related]
7. Interspecies pharmacokinetic scaling of oltipraz in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics. Bae SK; Lee SJ; Kim YG; Kim SH; Kim JW; Kim T; Lee MG Biopharm Drug Dispos; 2005 Apr; 26(3):99-115. PubMed ID: 15723427 [TBL] [Abstract][Full Text] [Related]
8. [Attempt at potentiation of the action of L-dopa on the secretion of growth hormone by benserazide, disulfiram and propranolol]. Rochiccioli P; Enjaume P; Dutau G; Ribot C; Augier D Arch Fr Pediatr; 1976 Jan; 33(1):55-66. PubMed ID: 985031 [TBL] [Abstract][Full Text] [Related]
9. Interaction of tetrahydropapaveroline with inhibition of dopa-decarboxylase by Ro 4-4602 in brain: effects on alcohol drinking in the rat. Miñano FJ; McMillen BA; Myers RD Alcohol; 1989; 6(2):133-7. PubMed ID: 2713086 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and tissue distribution of ketanserin in rat, rabbit and dog. Michiels M; Monbaliu J; Meuldermans W; Hendriks R; Geerts R; Woestenborghs R; Heykants J Arzneimittelforschung; 1988 Jun; 38(6):775-84. PubMed ID: 3178917 [TBL] [Abstract][Full Text] [Related]
11. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism. Nutt JG; Woodward WR; Anderson JL Ann Neurol; 1985 Nov; 18(5):537-43. PubMed ID: 4073849 [TBL] [Abstract][Full Text] [Related]
12. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment. Silva MA; Mattern C; Häcker R; Tomaz C; Huston JP; Schwarting RK Synapse; 1997 Dec; 27(4):294-302. PubMed ID: 9372552 [TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics. Dingemanse J; Kleinbloesem CH; Zürcher G; Wood ND; Crevoisier C Br J Clin Pharmacol; 1997 Jul; 44(1):41-8. PubMed ID: 9241095 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of triclopyr (3,5,6-trichloro-2-pyridinyloxyacetic acid) in the beagle dog and rhesus monkey: perspective on the reduced capacity of dogs to excrete this organic acid relative to the rat, monkey, and human. Timchalk C; Nolan RJ Toxicol Appl Pharmacol; 1997 Jun; 144(2):268-78. PubMed ID: 9194410 [TBL] [Abstract][Full Text] [Related]
16. Levodopa pharmacokinetics and dyskinesias: are there sex-related differences? Martinelli P; Contin M; Scaglione C; Riva R; Albani F; Baruzzi A Neurol Sci; 2003 Oct; 24(3):192-3. PubMed ID: 14598082 [TBL] [Abstract][Full Text] [Related]
17. [Urinary excretion of 3,4-dihydroxyphenyl-alanine, 3-O-methyldopa, dopamine and homovanillic acid in man. Effects of an inhibitor of decarboxylase of aromatic amino acids (Benserazide) (author's transl)]. Geissbühler F; Widmer J J Clin Chem Clin Biochem; 1976 Nov; 14(11):543-7. PubMed ID: 1003116 [TBL] [Abstract][Full Text] [Related]
18. Plasma nicotine pharmacokinetics in dogs after intravenous administration: determination by radioimmunoassay. Monji N; Castro A Res Commun Chem Pathol Pharmacol; 1979 Feb; 23(2):267-77. PubMed ID: 461952 [TBL] [Abstract][Full Text] [Related]
19. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys. Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675 [TBL] [Abstract][Full Text] [Related]
20. [Effect of L-dopa combined with benserazide on hemodynamics and motor activity in hypoxic rats]. Boismare F; Le Poncin M; Belliard JP; Hacpille L C R Seances Soc Biol Fil; 1975; 169(1):203-8. PubMed ID: 126730 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]